Aptinyx Pulls Back From Neuropsychiatry After Mid-Stage PD Failure
Prioritizes Cutting Costs
The US firm has faced yet another clinical setback as its Phase II candidate, NYX-458, failed to improve cognitive impairment in patients with Parkinson’s disease and Alzheimer’s, triggering the cessation of its only other program as priorities shift to preserving funds.
